An interventional study of Progressive supervised weight training and Lecture in Prostate Cancer, sponsored by Tampere University Hospital. Status unknown at 1 site in Finland. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-11.
Sponsored by Tampere University Hospital · Not applicable, Interventional, and Treatment
This study evaluates effects of supervised exercise in reducing adverse effects of hormonal treatment, increasing quality of life and in inducing a long-term change into more active lifestyle in prostate cancer patients on androgen deprivation therapy. All participants will attend a starting lecture at the beginning of the trial, after which they are randomly allocated to attend 3 months of either supervised or non-supervised exercise program. Leisure time activity, quality of life, blood sugar and cholesterol values, and body composition of participants will be evaluated at three time-points; at recruitment, after 12 weeks and after 24 weeks. Effects on quality of life will also be qualitatively evaluated with single- and group interviews.
Androgen deprivation therapy (ADT) is commonly used in management of advanced or recurrent prostate cancer. It also frequently used adjuvant to curative-intent radiation therapy for localized prostate cancer. Low testosterone levels during androgen deprivation commonly cause adverse effects reducing quality of life. Most common adverse effects include fatigue, weight gain, loss of lean muscle mass, hyperglycemia and hypercholesterolemia.
Regular exercise, especially programs involving combination of both aerobic exercise and resistance training has been shown to reduce to reduce adverse effects of ADT on physical functioning and quality of life. It may also improve disease prognosis.
The study compares effects of supervised and unsupervised exercise on plasma lipid parameters (total cholesterol, LDL, HDL and triglycerides) and glucose levels (fasting plasma glucose, glycated hemoglobin), overall quality of life and on average daily exercise activity in men with prostate cancer and under ADT. As secondary outcome we will study effect on continued exercise activity after the intervention, changes in body composition, blood pressure and risk of fractures, castration resistance as well as death due to prostate cancer and due to any cause.
Study hypothesis is that supervised exercise will improve quality of life, lipid and glucose parameters and increase daily exercise activity more that non-supervised exercise. We also expect higher continued exercise activity, greater changes in body composition and blood pressure and lowered risk of fractures and death in the supervised exercise group.
This is a randomized, controlled clinical trial. The study aims to recruit 40 men on ADT for prostate cancer. This will be a pilot study to estimate effect sizes in Finnish population to inform further larger trial.
All participants attend introductory lecture, where a urologist informs them about adverse effects of ADT and positive effects of exercise during ADT, exercise instructor gives advice for training both at home and in the gym and nutritional therapeutist tells about nutrition to overcome adverse effects of ADT and support training.
After the introductory lecture the participants are randomized 1:1 to either the supervised or non-supervised exercise group (Figure). Men in the supervised group participate in progressive group exercise sessions twice a week for total of 12 weeks at the Varala sports academy in Tampere, Finland. Each exercise session includes both aerobic and resistance training targeting all major muscle groups (Additional document I, exercise program). The non-supervised group will exercise independently for 12 weeks according to the instructions given at the introductory lecture. The first control visit will be after this first period of 12 weeks of exercise.
After the first follow-up visit both group will continue non-supervised exercise for 12 weeks, after which the second control visit will be arranged. Special focus on the second control visit is to see how many in each group has been able to carry on active exercising, i.e. has the intervention promoted long-term change in exercise activity.
Both study group will be given Polar wrist activity monitors to be used 24 h/day for the entire course of the study.
All participants are asked to fill validated quality of life surveys EORTC QLQC-30 (overall quality of life) and EORTC QLQC-PR25 (prostate cancer-specific quality of life) at baseline and again at 1st and 2nd control visits. Additionally, qualitative evaluation of quality of life as well as perceived possibilities and obstacles for exercise are evaluated in individual- and group interviews during the study visits. Plasma lipid and glucose parameters, blood pressure and body composition will be measured at each of these visits.
At each visit a separate blood sample is taken and stored for future measurement of biomarkers associated with prostate cancer progression, glucose and lipid metabolism and effects of exercise.
6,484 studies on the registry are indexed under Prostatic Neoplasms; 1,415 are open to participants now.
This study's planned enrollment of 40 is below the median of 58 across 4,908 interventional studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Tampere University Hospital is the lead sponsor of 211 studies on the registry; 55 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Informational initiation lecture and supervised exercise twice a week for 12 weeks followed by 12 weeks of non-supervised exercise.
Other: Progressive supervised weight training · Other: Lecture
Informational initiation lecture and only non-supervised exercise
Other: Lecture
12 weeks of progressive weight training twice a week supervised by a qualified physiotherapist.
Urologist informs participants on adverse effects of castration treatments and benefits of regular exercise. Physiotherapist gives an exercise program to follow at home, and nutritionist informs patients on correct nutrition to assist physical exercise.
Daily total activity
Daily activity as measured by wrist activity monitor worn by the participants at all times during the study. Measured as metabolic equivalents of task (MET) units. Range from 0.9 to 23.
Time frame: At randomization and twice more at 12 week intervals
Fasting plasma total cholesterol
Value measure in mmol/l
Time frame: At randomization and twice more at 12 week intervals
Fasting plasma LDL cholesterol
Value measure in mmol/l
Time frame: At randomization and twice more at 12 week intervals
Fasting plasma HDL cholesterol
Value measure in mmol/l
Time frame: At randomization and twice more at 12 week intervals
Fasting plasma triglycerides
Value measure in mmol/l
Time frame: At randomization and twice more at 12 week intervals
Fasting plasma glucose level
Value measured in mmol/l
Time frame: At randomization and twice more at 12 week intervals
Blood glycated hemoglobin (HbA1C) level
Value measured in mmol/mol
Time frame: At randomization and twice more at 12 week intervals
Overall quality of life
Score from validated survey EORTC QLQ-C30, score range from 0-100, with 100 denoting the highest quality of life
Time frame: At randomization and twice more at 12 week intervals
Prostate cancer-specific quality of life
Score from validated survey EORTC QLQ-PR25, score range from 0-100, with 100 denoting the highest quality of life
Time frame: At randomization and twice more at 12 week intervals
Change in daily activity after the intervention
Change in daily activity of the supervised exercise group after completion of 12 weeks of supervised exercise as measured by wrist activity monitor in MET units, range from 0.9 to 23.
Time frame: Measured daily for 12 weeks' time after the intervention
Subjective adverse effects of castration treatment
The effect of supervised exercise on subjective adverse effects of castration treatment for prostate cancer. Qualitative assessment in three individual interviews and one group interview. No scaling used as this is a qualitative rather than quantitative end-point
Time frame: At randomization and twice more at 12 week intervals
Lean body mass
Bioimpedance-based measurement of lean body mass as percentage of total body mass measured with TANITA MC-780 device
Time frame: At randomization and twice more at 12 week intervals
Muscle mass
Bioimpedance-based measurement of muscle mass as percentage of total body mass measured with TANITA MC-780 device
Time frame: At randomization and twice more at 12 week intervals
Skeletal mass
Bioimpedance-based measurement of skeletal mass as percentage of total body mass measured with TANITA MC-780 device measured with TANITA MC-780 device
Time frame: At randomization and twice more at 12 week intervals
Fat mass
Bioimpedance-based measurement of fat mass as percentage of total body mass measured with TANITA MC-780 device measured with TANITA MC-780 device
Time frame: At randomization and twice more at 12 week intervals
Metabolic age
Metabolic age measured with bioimpedance-based TANITA MC-780 device
Time frame: At randomization and twice more at 12 week intervals
Systolic blood pressure
Value measured in mmHg
Time frame: At randomization and twice more at 12 week intervals
Diastolic blood pressure
Value measured in mmHg
Time frame: At randomization and twice more at 12 week intervals
Time to castration resistance
Time to castration resistance as defined by two consecutive rising PSA levels and increase of 50% or more from the nadir. Measured as months between the study recruitment and first record of castration resistance. Information obtained from patient files.
Time frame: Followed yearly for up to 15 years from randomization
Time to death
Time to death due to any cause. Measured as months between the study recruitment and date of death. Information obtained from patient files and national death certificate registry.
Time frame: Followed yearly for up to 15 years from randomization
Time to prostate cancer death
Time to death due to prostate cancer. Measured as months between the study recruitment and date of death. Information obtained from patient files and national death certificate registry.
Time frame: Followed yearly for up to 15 years from randomization
Bone fractures
Occurrence of any bone fracture requiring either conservative or operative management. Information obtained from patient files and national hospital discharge registry. Fracture site and it's management are recorded.
Time frame: Followed yearly for up to 15 years from randomization
Documents are hosted by the registry — open the source record to download them.
Plan to share: No — IPD will not be shared since it is prohibited by the ethics board and by patient consent
Started Aug 2019 (actual). Primary completion is estimated for Aug 2020, 12 months after the start.
Of 1,018 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 87. This study's planned 12 months is below that.
Counting every sponsor, half of 1,063 studies reached it within 45 months; a quarter within 22 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.